Unlike PPARγ, PPARα or PPARβ/δ activation does not promote human monocyte differentiation toward alternative macrophages

Biochemical and Biophysical Research Communications

Volumn 386, Issue 3, 2009, Pages 459-462

  Bouhlel, Mohamed Amine ^a,b,c   Brozek, John ^d   Derudas, Bruno ^a,b,c   Zawadzki, Christophe ^b   Jude, Brigitte ^b   Staels, Bart ^a,b,c   Chinetti Gbaguidi, Giulia ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Parc Eurasante Lille Metropole   (France)

Author keywords

Atherosclerosis; Macrophages; Nuclear receptors

Indexed keywords

CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; BIOSYNTHESIS; CELL CULTURE; DRUG POTENTIATION; GENETICS; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM;

MUS;

ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MONOCYTES; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PPAR-BETA;

EID: 67650272363     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.047     Document Type: Article

References (18)

1. Van Ginderachter J.A., Movahedi K., Hassanzadeh Ghassabeh G., Meerschaut S., Beschin A., Raes G., and De Baetselier P. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211 (2006) 487-501
2. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3 (2003) 23-35
3. Mantovani A., Locati M., Vecchi A., Sozzani S., and Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 22 (2001) 328-336
4. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., Zawadski C., Jude B., Torpier G., Marx N., Staels B., and Chinetti-Gbaguidi G. PPARg activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6 (2007) 137-143
5. Duval C., Chinetti G., Trottein F., Fruchart J.C., and Staels B. The role of PPARs in atherosclerosis. Trends Mol. Med. 8 (2002) 422-430
6. Lee C.H., Kang K., Mehl I.R., Nofsinger R., Alaynick W.A., Chong L.W., Rosenfeld J.M., and Evans R.M. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc. Natl. Acad. Sci. USA 103 (2006) 2434-2439
7. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., Gonzalez F.J., Ham J., Kang H., Peters J.M., and Evans R.M. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. USA 103 (2006) 3444-3449
8. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr. Opin. Lipidol. 14 (2003) 459-468
9. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Eagle A.R., Vats D., Brombacher F., Ferrante A.W., and Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (London) 447 (2007) 1116-1120
10. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., Folian B., Subramaniam S., Gonzalez F.J., Glass C.K., and Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117 (2007) 1658-1669
11. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., and Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7 (2008) 485-495
12. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., Subramanian V., Mukundan L., Ferrante A.W., and Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7 (2008) 496-507
13. Zawadzki C., Susen S., Richard F., Haulon S., Corseaux D., Jeanpierre E., Vincentelli A., Lucas C., Torpier G., Martin A., Van Belle E., Staels B., and Jude B. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 195 (2007) e117-e125
14. Chinetti G., Griglio S., Antonucci M., Pineda Torra I., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., and Staels B. Activation of peroxisome proliferator-activated receptors a and g induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273 (1998) 25573-25580
15. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
16. Oliver W.R.J., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98 (2001) 5306-5311
17. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver Jr. W.R., and Sternbach D.D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13 (2003) 1517-1521
18. Rigamonti E., Chinetti-Gbaguidi G., and Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1050-1059